Superworth

Orasure Technologies OSUR

Medical - Instruments & Supplies, Healthcare
$3.46
−12.31%
Market cap
$238.3M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.1×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$112.4M
−19% on a year ago
Net margin
−43.7%
Free cash flow yield
−20.2%

Orasure Technologies trades at 2.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $112.4M over the last twelve months, down 19% on a year earlier with a −44% net margin.

Charts

Financials

Income statement for OSUR, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$89.2M−23%$75.9M−38%$54.1M−65%$54.3M−36%$39.9M−55%$37.4M−51%$29.9M−45%$31.2M−43%$27.1M−32%$26.8M−29%$27.9M−7%$30.6M−2%
Cost of revenue$44.8M−36%$40.8M−44%$30.1M−66%$29.6M−50%$22.8M−49%$23.9M−41%$17.6M−41%$18.1M−39%$15.3M−33%$15.8M−34%$16.1M−9%$17.3M−4%
Gross profit$44.3M−5%$35.1M−30%$24.1M−63%$24.7M−6%$17.1M−62%$13.6M−61%$12.3M−49%$13.2M−47%$11.8M−31%$11M−19%$11.8M−4%$13.3M+1%
R&D$8.5M−16%$7M−13%$7.7M−27%$6.6M−14%$5.6M−34%$6.1M−13%$9.6M+24%$11.4M+73%$10.1M+80%$11.4M+88%$13.7M+42%$9.4M−17%
SG&A$18.8M−35%$20.9M−23%$20.1M−33%$19.8M−21%$17.4M−7%$19.9M−5%$21M+4%$19.1M−4%$17.4M−0%$16.4M−18%$21.3M+2%$21M+10%
$10.9M+1158%$3.9M−73%−$7.1M−$2.7M−57%−$6M−$12.4M−$17.8M+150%−$18M+558%−$16.1M+168%−$20.1M+62%−$23.3M+31%$5.4M
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income$13.5M+203%$20.7M+33%−$3.6M$326K−$3.2M−$9.5M−$16M+343%−$16.9M−$13.3M+313%−$18.4M+94%−$21.7M+36%$6.8M
$2.3M$647K−$18K−92%$381K$678K−71%$758K+17%−$456K+2433%$2M+425%$47K−93%$210K−72%−$432K−5%$55K−97%
Net income$11.2M+99%$20.1M+27%−$3.6M−$615K−87%−$4.5M−$10.8M−$16M+348%−$19.7M+3102%−$13.7M+204%−$19.3M+79%−$22.4M+40%$6.2M
$0.15+88%$0.27+23%−$0.05−$0.01−86%−$0.06−$0.14−$0.21+320%−$0.26+2500%−$0.19+217%−$0.27+93%−$0.32+52%$0.09
74.3M+2%75M+3%73.9M+0%74.2M+1%74.6M+0%74.7M−0%74.9M+1%74.5M+1%73M−2%71.6M−4%69.7M−7%70.2M−6%

EPS, diluted: 8 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 10 periods, Q4 FY11 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Orasure Technologies' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
OSUROrasure Technologies$238.3Mn/m28.9×2.1×−19%−43.7%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
TCMDTactile Systems Technology$518.1M21.2×62.3×1.5×+17%7.1%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
Peer median$313.2M19.4×18.7×1.3×+5%6.9%

More on Orasure Technologies

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .